LG Chem is positioning artificial intelligence (AI) as a central engine in the entire drug development process. The company aims to enhance the success rate of new drug development by utilizing AI not only for candidate substance discovery but also for selecting patients for clinical trials.
On October 20, LG Chem announced the hosting of the '2026 LG AI Bio Conference' at LG Science Park in Gangseo-gu, Seoul, in collaboration with the LG AI Research Institute and U.S. biotech venture capital firm Flagship Pioneering. This inaugural event, aimed at fostering the domestic AI bio ecosystem and expanding global collaboration, attracted over 140 participants from AI bio companies both domestically and internationally.
In his opening remarks, Son Ji-woong, President of LG Chem's Life Sciences Division, stated, "AI is evolving from a tool for drug development to a core engine that determines competitiveness. In the future, finding patients with high treatment efficacy using AI will be a key competitive advantage, rather than just identifying structurally superior drugs."
LG Chem is particularly focused on precision oncology. Since tumors exhibit different biological characteristics among patients, the same drug can have varying effects. The company plans to leverage AI to discover biomarkers that indicate disease states, allowing for precise patient selection and the development of treatment strategies. The better the selection of clinical trial patients, the higher the likelihood of clinical success.
A key project in AI drug development is the personalized messenger RNA (mRNA) cancer vaccine. The company is advancing a model that predicts patient-specific neoantigens, which elicit immune responses against cancer cells. LG Chem aims to complete preclinical trials next year and enter full clinical stages by 2029.
The global industry also recognizes that AI is fundamentally changing drug development methods. Andre Andonian, Chairman of Flagship Pioneering Asia-Pacific, remarked, "Examples like Moderna and Lyra Science demonstrate that AI has become a core driver of corporate growth."
Silico Medicine shared a case of advancing candidate substances identified through generative AI to clinical stages, while Lyra Science introduced the concept of an 'autonomous laboratory' where AI agents independently design, synthesize, experiment, and learn. During a panel discussion, Lee Jung-seok, CEO of InnoKras, and Na Kwon-jung, Chief Medical Officer of Portera, presented strategies for patient selection using genomic data and spatial biology-based AI.
On October 20, LG Chem announced the hosting of the '2026 LG AI Bio Conference' at LG Science Park in Gangseo-gu, Seoul, in collaboration with the LG AI Research Institute and U.S. biotech venture capital firm Flagship Pioneering. This inaugural event, aimed at fostering the domestic AI bio ecosystem and expanding global collaboration, attracted over 140 participants from AI bio companies both domestically and internationally.
In his opening remarks, Son Ji-woong, President of LG Chem's Life Sciences Division, stated, "AI is evolving from a tool for drug development to a core engine that determines competitiveness. In the future, finding patients with high treatment efficacy using AI will be a key competitive advantage, rather than just identifying structurally superior drugs."
LG Chem is particularly focused on precision oncology. Since tumors exhibit different biological characteristics among patients, the same drug can have varying effects. The company plans to leverage AI to discover biomarkers that indicate disease states, allowing for precise patient selection and the development of treatment strategies. The better the selection of clinical trial patients, the higher the likelihood of clinical success.
A key project in AI drug development is the personalized messenger RNA (mRNA) cancer vaccine. The company is advancing a model that predicts patient-specific neoantigens, which elicit immune responses against cancer cells. LG Chem aims to complete preclinical trials next year and enter full clinical stages by 2029.
The global industry also recognizes that AI is fundamentally changing drug development methods. Andre Andonian, Chairman of Flagship Pioneering Asia-Pacific, remarked, "Examples like Moderna and Lyra Science demonstrate that AI has become a core driver of corporate growth."
Silico Medicine shared a case of advancing candidate substances identified through generative AI to clinical stages, while Lyra Science introduced the concept of an 'autonomous laboratory' where AI agents independently design, synthesize, experiment, and learn. During a panel discussion, Lee Jung-seok, CEO of InnoKras, and Na Kwon-jung, Chief Medical Officer of Portera, presented strategies for patient selection using genomic data and spatial biology-based AI.
* This article has been translated by AI.
Copyright ⓒ Aju Press All rights reserved.